Toll Free: 1.844.299.0030

Review of Avandia (rosiglitazone) and Cardiovascular Safety

Avandia Safety Announcement

The Federal Drug Administration has issued Safety Communication concerning the ongoing review of the drug Avandia (rosiglitazone) as it relates to cardiovascular safety.

Avandia is the brand name of an oral drug called rosiglitazone. Avandia is anti-diabetic drug in the thiazolidinedione class of drugs.  The drug is used to treat Type 2 diabetes.

Thiazolidinediones act as “insulin sensitizers,”  helping the body’s cells become more sensitive to insulin and thereby reduce glucose in the blood stream.

The FDA issued a safety communication concerning the possible association between rosiglitazone and an increased cardiovascular risk or risk of heart attack.

Click Here to Read the Safety Announcement:

Leave a Reply

Latest Posts

SSL Secure Site

Positive SSL on a transparent background

Accident Lawyer

We represent those seriously injured in accidents throughout the New York City metropolitan area.

Resource Center

Take us with you!

Social Media

Google+ tumblr img_logo_bluebg_2x facebook4
linkedin Twitter Youtube


Attorney Advertising